Types of Glucose Monitors — Physician-Reviewed 2026: CGM vs Flash vs OTC

Introduction

TL;DR — The Short Answer

Glucose monitors fall into four categories: continuous CGMs (real-time alerts, prescription required), flash monitors (scan-on-demand, prescription required), traditional blood glucose meters (fingerstick, no prescription), and OTC CGMs (real-time, no prescription, non-insulin users only). The right choice depends on your diagnosis, insulin use, and whether you need 24/7 hypoglycemia alerts. Use the Quick Match table below to find your fit in under 60 seconds.

If you’ve been recently diagnosed with diabetes — or you’re researching metabolic health monitoring for the first time — you’re likely confronting the same confusing landscape: device names that mean nothing yet, insurance questions you don’t know how to ask, and a provider recommendation you want to fully understand before your next appointment.

This guide organizes everything around four questions real people ask before choosing a glucose monitor:

1. What are the different types of glucose monitors, and how do they actually work?
2. Which type fits my specific situation — diagnosis, insulin use, and lifestyle?
3. What will it cost, with and without insurance?
4. Do I need a prescription, or can I buy one directly at a pharmacy?

All content has been medically reviewed by Dr. Rishav Das, M.B.B.S., with named clinical citations for every accuracy and outcomes claim. Jump to any section using the navigation above, or use the Quick Match tool below to identify your device type in under 60 seconds.

This guide provides evidence-based information on glucose monitoring devices, their mechanisms, and selection considerations. It complements—but does not replace—professional medical advice. Always consult your healthcare provider before selecting or changing glucose monitoring methods, as individual needs vary based on diabetes type, treatment regimen, and personal health factors.

All devices reviewed on this page were purchased at market price with no manufacturer funding or affiliate relationships, in accordance with our conflict of interest policy.

The Problem with Fingerstick-Only Monitoring

A traditional meter gives you a snapshot. A CGM gives you a movie.

The clinical limitation of fingerstick monitoring is well-documented: people who test with fingerstick meters — even diligently, four or more times daily — typically capture only a fraction of hypoglycemia and hyperglycemia events that occur between tests. Nocturnal hypoglycemia in particular is almost entirely invisible to fingerstick monitoring, because most people do not test during sleep.

In a 2019 randomized controlled trial, adults with Type 1 diabetes who switched from fingerstick monitoring to CGM experienced a 43-minute-per-day reduction in time spent in hypoglycemia, without worsening overall glycemic control (Beck et al., 2019, JAMA). The mechanism is simple: real-time trend arrows tell users their glucose is dropping before a hypoglycemic event occurs, enabling a preventive response.

For people who are symptomatic and testing frequently, this shift from reactive to predictive monitoring is often described as the most significant change in their diabetes management.

What Real-Time Glucose Data Changes for Daily Life

For insulin users: Trend arrows showing glucose direction (rising, stable, falling) allow for more precise pre-meal and correction dose decisions than a single point-in-time reading provides.

For non-insulin users: Seeing how specific foods, activity levels, stress, and sleep affect glucose in real time provides a behavior-feedback loop that no other tool currently replicates. This is the primary driver behind the growth of OTC CGM use in people without diabetes.

For caregivers and parents: Remote sharing features (Dexcom Share, Abbott LibreLink) allow a caregiver or parent to monitor a child’s or family member’s glucose readings on their own device — enabling school-day monitoring and overnight alerts without requiring the user to initiate the share themselves.

For athletes: Glucose trend data during exercise helps athletes identify the glucose-performance relationship specific to their sport, training load, and fueling strategy — a level of metabolic detail not achievable with any non-CGM device.

The switch from fingerstick to CGM is not right for everyone. Cost, insurance coverage, device comfort, and the clinical need for continuous monitoring all factor into the decision. The sections below are designed to help you identify which type of glucose monitoring — if any — is the right match for your situation.

Quick Match: Find Your Device Type

Not sure where to start? Answer two questions — your diagnosis category and insulin use — to find the recommended device type in under 60 seconds. Every recommendation links to the full section below.

Cost estimates reflect approximate 2026 out-of-pocket figures. Insurance coverage varies significantly by plan. See the Cost and Insurance section for full detail.

Not sure which row fits you? The Device Selection by Clinical Use Case section below walks through each scenario in detail, including what questions to ask your provider.

Continuous Glucose Monitors (CGM)

TL;DR:

A continuous glucose monitor (CGM) is a wearable sensor that automatically measures interstitial glucose every 1–5 minutes via a small filament placed just beneath the skin, transmitting real-time readings to a smartphone or dedicated receiver for up to 14 days without fingerstick calibration. Prescription CGMs — including the Dexcom G7 and FreeStyle Libre 3 — are the most clinically validated glucose monitoring option available, with reported MARD values of 8.2% and 7.9% respectively (Wadwa et al., 2022; Castorino et al., 2022, Diabetes Technology & Therapeutics).

What is a continuous glucose monitor (CGM)? A continuous glucose monitor (CGM) is a wearable medical device that automatically measures interstitial glucose every 1–5 minutes via a small filament sensor placed just beneath the skin, transmitting real-time readings to a smartphone or dedicated receiver for up to 14 days — without routine fingerstick calibration.

Prescription CGMs are the most clinically validated glucose monitoring technology currently available. The Dexcom G7 has a reported Mean Absolute Relative Difference (MARD) of 8.2% (Wadwa et al., 2022, Diabetes Technology & Therapeutics) and the FreeStyle Libre 3 reports approximately 7.9% MARD (Castorino et al., 2022, Diabetes Technology & Therapeutics). Both require a prescription and are intended for people managing diabetes with or without insulin.

Who CGMs are best for: People with Type 1 diabetes, people with Type 2 diabetes on insulin, anyone requiring automated hypoglycemia alerts, pregnant people with diabetes, and athletes or active users who need continuous overnight monitoring.

Device Characteristics

Key CGM Systems (Current Market)

• Eversense: 90-180 day implantable sensor (requires minor procedure)
• Dexcom G7: 10-day sensor, 5-minute readings, no calibration required
• FreeStyle Libre 3: 14-day sensor, 1-minute readings, no calibration required
• Medtronic Guardian Connect: 7-day sensor, may require calibration

Life-Changing Benefits of Continuous Monitoring:

Beyond clinical improvements, CGM users report significant lifestyle enhancements:

• Sleep Through the Night with Confidence
  Programmable alerts notify users before glucose reaches dangerous levels, allowing uninterrupted sleep while maintaining safety. Parents can monitor children remotely through smartphone apps, reducing nighttime anxiety without constant physical checks.
• See Food Impact in Real-Time
  Watch how different meals affect glucose levels within minutes rather than waiting hours to test. This immediate feedback helps identify problem foods and portion sizes, making dietary adjustments more intuitive and effective.
• Exercise Without Guesswork
  Check glucose levels before, during, and after physical activity without interrupting workouts for finger pricks. Athletes and active individuals can identify patterns showing when they need pre-exercise snacks or post-workout adjustments.
• Dramatically Fewer Finger Pricks
  Modern CGM systems like Dexcom G7 and FreeStyle Libre 3 require zero fingerstick calibrations. Users who previously tested 8-10 times daily often reduce to zero routine finger pricks, reserving traditional meters only for occasional confirmation when needed.
• Better Long-Term Control
  Clinical research demonstrates CGM users typically achieve 0.3-0.5% HbA1c improvements compared to traditional monitoring. This reduction translates to meaningful decreases in long-term complication risks, including neuropathy, retinopathy, and cardiovascular disease. (peer-reviewed research on continuous glucose monitoring outcomes) ( American Diabetes Association’s 2024 standards for glycemic targets)
• Early Warning of Dangerous Trends
  Trend arrows and predictive alerts warn users when glucose is dropping rapidly or rising persistently—not just when it crosses a threshold. This advance notice enables preventive action rather than reactive crisis management.

meta-analysis of CGM’s impact on quality of life in Type 2 diabetes

Ready to Move Forward?
✓ Discuss with your doctor: Bring this guide to your next appointment to discuss which device type fits your treatment plan
✓ Check insurance coverage: Call your insurance to verify CGM/meter coverage and copay amounts
✓ Explore manufacturer resources: Visit [device name] manufacturer website for detailed specifications and patient support programs

Flash Glucose Monitors

TL;DR:

Flash monitors use the same sensor technology as CGMs but require you to scan the sensor with your phone to see readings (not automatic). Sensors last 14 days. Cost: $100-150/month without insurance, $25-75/month with coverage. Provides trend graphs and directional arrows but limited automatic alerts. Best for budget-conscious users wanting more data than fingersticks provide, or Type 2 diabetes patients not requiring intensive alarm features.

What is a flash glucose monitor? A flash glucose monitor measures interstitial glucose continuously but only displays a reading when you actively scan the sensor — typically with a smartphone or dedicated reader. Unlike a CGM, flash monitors do not send automatic alerts if glucose drops dangerously low; you must initiate each reading manually.

The FreeStyle Libre 2 and FreeStyle Libre 3 are the most widely used flash monitors in the United States, though the Libre 3 now also supports optional real-time alerts, blurring the line between flash and full CGM functionality. Flash monitors require a prescription and are most commonly used for Type 1 and Type 2 diabetes management.

Flash vs CGM — the key difference: CGMs push continuous alerts to your device automatically; flash monitors require a manual scan. For people who do not need alarm-based hypoglycemia alerts, flash monitors offer equivalent glucose trend data at a comparable cost, with a smaller sensor footprint on most body sites.

Who flash monitors are best for: People with Type 2 diabetes on oral medications or non-intensive insulin regimens, individuals who prefer scanning over receiving continuous alerts, and people transitioning from traditional meters who want trend data without full CGM complexity.

Technology Overview

Ready to Move Forward?
✓ Discuss with your doctor: Bring this guide to your next appointment to discuss which device type fits your treatment plan
✓ Check insurance coverage: Call your insurance to verify CGM/meter coverage and copay amounts
✓ Explore manufacturer resources: Visit [device name] manufacturer website for detailed specifications and patient support programs

Traditional Blood Glucose Meters

TL;DR:

Traditional meters require finger-prick blood samples and provide one reading per test. No ongoing sensor costs—just test strips ($20-100/month for typical testing frequency). Most accurate method for single-point readings. Best for infrequent testing needs, budget constraints, backup monitoring, or situations requiring confirmed blood glucose values. Universally covered by insurance with minimal copays.

What is a traditional blood glucose meter? A traditional blood glucose meter measures glucose directly from a small blood sample taken by a fingerstick lancet, providing a single point-in-time reading. Unlike CGMs and flash monitors, traditional meters measure capillary blood glucose — not interstitial glucose — which means they reflect true blood glucose without the 5–15 minute physiological lag common to sensor-based devices.

Traditional meters do not require a prescription and are available at any pharmacy, typically at low upfront cost ($15–$50 for the meter; $0.25–$1.00 per strip). They remain the most accurate point-in-time glucose measurement available outside a clinical laboratory.

Do you still need a traditional meter if you use a CGM? For most CGM users, fingerstick testing is recommended in two situations: (1) when CGM readings conflict with physical symptoms (e.g., sweating or confusion despite a CGM reading in range), and (2) during the CGM sensor warm-up period. Most endocrinologists recommend keeping a traditional meter as a backup, even for full-time CGM users.

Who traditional meters are best for: People managing diabetes on a strict budget, individuals in regions where CGM reimbursement is limited, and anyone using a CGM who wants a backup device for symptom-conflict confirmation.

Measurement Process

Step-by-Step Operation:

1. Insert test strip into meter
2. Obtain blood sample via fingerstick lancet
3. Apply blood drop to test strip
4. Meter analyzes blood glucose via enzymatic reaction
5. Result displays in 5-10 seconds

Meter Categories

Ready to Move Forward?
✓ Discuss with your doctor: Bring this guide to your next appointment to discuss which device type fits your treatment plan
✓ Check insurance coverage: Call your insurance to verify CGM/meter coverage and copay amounts
✓ Explore manufacturer resources: Visit [device name] manufacturer website for detailed specifications and patient support programs

Over-the-Counter (OTC) CGMs — No Prescription Required

TL;DR:

As of 2026, three CGMs are available in the United States without a prescription: Dexcom Stelo (cleared for adults not using insulin), Abbott Lingo (positioned for metabolic wellness in non-insulin users), and Abbott FreeStyle Libre Rio (cleared for adults with Type 2 diabetes not on insulin). OTC CGMs provide real-time continuous glucose monitoring but do not include the automatic hypoglycemia alarm functionality required for insulin-dependent management. Anyone who uses insulin — for Type 1 or Type 2 diabetes — requires a prescription CGM.

Can you buy a CGM without a prescription? Yes. As of 2026, three CGMs are FDA-cleared for sale in the United States without a prescription: Dexcom Stelo, Abbott Lingo, and Abbott FreeStyle Libre Rio. All three are available at major pharmacy chains and directly from manufacturer websites — no provider visit required.

OTC CGMs are real-time continuous glucose monitors — they measure interstitial glucose every few minutes and display trend data on a paired smartphone app, the same core technology as prescription CGMs. The key differences are regulatory category, alarm capability, and intended user population.

Who OTC CGMs are designed for:

• Adults with Type 2 diabetes who are not using insulin to manage their condition
• People with prediabetes monitoring blood sugar trends
• People without any diabetes diagnosis who are using CGM for metabolic health or athletic performance monitoring

Who OTC CGMs are NOT designed for:

• People with Type 1 diabetes
• Anyone using insulin (any type, any regimen)
• Anyone requiring automated low-glucose alarm alerts for safety

If you use insulin or have Type 1 diabetes, you need a prescription CGM. OTC devices do not provide the alarm-based hypoglycemia alerting required for insulin-dependent management.

Dexcom Stelo vs Abbott Lingo — Key Differences

Dexcom Stelo is best suited for people with Type 2 diabetes (non-insulin) who want a familiar device brand with straightforward glucose trend reporting, and who may already be in the Dexcom ecosystem.

Abbott Lingo is positioned more broadly for metabolic wellness — its app integrates food and activity logging more prominently, and it targets health-conscious users beyond the diagnosed diabetes population.

Abbott FreeStyle Libre Rio is Abbott’s dedicated OTC device for adults with Type 2 diabetes not using insulin — it runs on the same FreeStyle Libre sensor platform as the prescription Libre 3 but is sold as an OTC product with a simplified app experience.

Note: OTC CGM sensor accuracy data from independent MARD studies is more limited than for prescription devices. Dexcom Stelo has reported MARD performance comparable to prescription CGMs in company-sponsored studies; independent peer-reviewed MARD data for Stelo and Lingo should be reviewed as it becomes available.

What “iCGM” and “FDA-Cleared” Mean for Device Selection

What is an iCGM? An interoperable CGM (iCGM) is a continuous glucose monitor that meets a specific FDA performance standard (Special Controls, 21 CFR 862.3360), enabling it to integrate directly with other FDA-cleared diabetes devices — including insulin pumps and automated insulin delivery (AID) systems. Only prescription CGMs can be classified as iCGMs.

The Dexcom G7 and FreeStyle Libre 3 are both iCGM-cleared. This means they can be paired with compatible AID systems (e.g., Omnipod 5, Tandem Control-IQ) to enable closed-loop insulin delivery — a capability entirely unavailable to OTC CGMs.

FDA-cleared vs FDA-approved: All currently marketed CGMs are FDA-cleared (via the 510(k) pathway), not FDA-approved (via the PMA pathway). “FDA-cleared” means the device has been reviewed and determined to be substantially equivalent to a legally marketed predicate device in safety and efficacy. Both clearance statuses are rigorous regulatory processes; the distinction does not indicate that one is safer than the other.

What this means for your device choice:

• If you use an insulin pump or AID system, you need an iCGM-compatible prescription device
• If you do not use insulin, iCGM compatibility is irrelevant to your selection decision
• OTC CGMs (Stelo, Lingo, Libre Rio) are FDA-cleared but not iCGM-classified — they cannot integrate with insulin delivery devices

Top-Rated Glucose Monitors by Category (2026)

Based on clinical accuracy data, user ratings, and evidence-based outcomes:

Best Overall Continuous Glucose Monitor: Dexcom G7

• Why It Leads: 10-day sensor life, 8.1% MARD accuracy, most comprehensive alert system, shortest warm-up time (30 minutes), extensive insurance coverage. clinical accuracy study of the Dexcom G7 system
• Best For: Type 1 diabetes, insulin pump users, individuals prone to hypoglycemia, parents monitoring children remotely
• Typical Cost: $350-400/month without insurance; $35-100/month with insurance coverage
• User Advantage: No calibration required, real-time sharing with up to 10 followers, integration with insulin pumps

Best Budget CGM Option: FreeStyle Libre 3

• Why It Stands Out: 14-day sensor life (longest available), 9.2% MARD accuracy, lowest monthly CGM cost, 1-minute reading frequency (clinical evaluation of 14-day sensor accuracy)
• Best For: Type 2 diabetes, cost-conscious users seeking continuous monitoring, those not requiring extensive alert customization
• Typical Cost: $200-300/month without insurance; $25-75/month with insurance
• User Advantage: Smallest sensor available, simple application process, growing insurance acceptance

Best Traditional Meter for Accuracy: Contour Next One

• Why Clinicians Recommend It: Second-chance sampling (add more blood to same strip if needed), proven accuracy across wide hematocrit ranges, smartphone connectivity with free app
• Best For: Individuals requiring fingerstick confirmation, those preferring traditional testing, budget-conscious users
• Typical Cost: $20-40/month for strips (testing 4x daily); meter often free
• User Advantage: No coding required, works with generic test strips, results in 5 seconds

Easiest to Use for Seniors and Beginners: FreeStyle Libre 2

• Why It’s Simple: One-button application, large display with clear numbers, optional alarms for safety, no smartphone required (receiver available)
• Best For: Older adults, those uncomfortable with technology, caregivers managing loved ones’ diabetes
• Typical Cost: $150-250/month without insurance; $35-75/month with Medicare or insurance
• User Advantage: Scan-based reading (no automatic alerts unless desired), 14-day sensor, simpler than full CGM systems

Best for Athletes and Active Lifestyles: Dexcom G7

• Why Athletes Choose It: IPX8 water resistance (swim-safe up to 8 feet for 24 hours), withstands high-intensity workouts, provides real-time glucose during exercise without interruption
• Best For: Runners, cyclists, swimmers, gym enthusiasts, outdoor workers
• Typical Cost: Same as Best Overall (above)
• User Advantage: Adhesive designed for movement and sweat, trend arrows show glucose direction during activity

Important Note: “Best” device varies by individual needs, insurance coverage, lifestyle, and diabetes type. These recommendations represent common user preferences and clinical evidence but should be discussed with your healthcare provider to ensure the choice aligns with your specific medical situation.

Next Steps Toward Purchase:

✓ Verify current prices: Device costs change frequently—check manufacturer websites or call DME suppliers for latest pricing
✓ Confirm insurance coverage: Contact your insurance provider with specific device model names to verify coverage
✓ Schedule diabetes educator appointment: Many insurers require diabetes education before approving CGM coverage
✓ Request trial if available: Some endocrinologists have 14-30 day sample sensors from manufacturers for trial before commitment

Side-by-Side Device Comparison: CGM vs Flash vs OTC vs Traditional Meter

MARD figures for prescription CGMs from Castorino et al. (2022) and Wadwa et al. (2022), Diabetes Technology & Therapeutics. OTC CGM independent MARD data is limited as of June 2026. Costs are estimates — verify current pricing before purchasing. [3 – 2021 randomized trial in Type 2 diabetes patients on basal insulin]

How CGMs Measure Glucose Continuously

Mechanism of Action

Physiological Lag Explanation

1. Blood glucose changes first
2. Glucose diffuses from capillaries to interstitial fluid
3. CGM sensor detects interstitial glucose
4. Reading appears on device 5-10 minutes after blood glucose change

This lag is clinically relevant during rapid glucose fluctuations. During stable periods, interstitial glucose closely mirrors blood glucose.

Sensor Lifespan and Replacement

CGM sensors have defined wear periods due to:

• Enzymatic activity degradation over time
• Tissue response at insertion site
• Foreign body reaction reducing sensor contact
• Manufacturer-validated accuracy windows

---

💬 Common Concern: “I’m worried about sensor failures during important moments—what if it stops working when I really need it?”

While sensor failures are uncommon (<2% monthly failure rate), smart users stay prepared:

Built-in safeguards:

• Systems alert you 12-24 hours before scheduled sensor expiration
• Low battery warnings give 1-4 hours notice before transmitter shutdown
• Most sensors give error alerts when experiencing technical issues

Your safety backup:

• Always keep: A traditional blood glucose meter with test strips—even long-time CGM users maintain backup meters
• Manufacturer support: All major brands replace faulty sensors free when you contact their 24/7 technical support hotline
• Treatment decisions: FDA recommends fingerstick confirmation before making treatment decisions during suspected sensor inaccuracy anyway

What experienced users do: Keep a small kit with backup meter, lancets, and strips in your bag or car. Most never need it, but the preparedness eliminates the worry.

How Flash Monitors Work (Scan-on-Demand)

How On-Demand Scanning Works

Scan Frequency Requirements

Flash monitors require scans at least every 8 hours to maintain continuous data. Longer intervals create data gaps. More frequent scanning provides more complete glucose patterns.

Alert Capabilities

Some flash systems offer optional glucose alerts through smartphone apps. Alert functionality varies by model and may require specific app configurations.

How Traditional Meters Measure Blood Glucose

Enzymatic Glucose Measurement

Blood glucose meters use one of two enzymatic reactions:

Glucose Oxidase Method:

• Enzyme reacts with glucose and oxygen
• Produces hydrogen peroxide
• Electrical current measured proportional to glucose

Glucose Dehydrogenase Method:

• Enzyme reacts with glucose
• Produces electrons directly
• Less oxygen-dependent than oxidase method

Both methods convert glucose concentration into electrical signals measured in 5-10 seconds.

Factors Affecting Meter Accuracy

• Blood sample size and application technique
• Hematocrit (red blood cell concentration)
• Altitude and oxygen levels
• Medication interference (some vitamins, acetaminophen)
• Test strip storage and expiration

How OTC CGMs Differ from Prescription-Class Devices

Key Characteristics

• No prescription required: Direct-to-consumer purchase
• Wellness focus: Marketed for metabolic health, not diabetes treatment
• Higher cost: Typically $199-$399/month including sensors and app
• Coaching included: Many programs offer nutritionist or health coach access
• App integration: Custom apps with meal logging, exercise tracking
• Not for diabetes treatment decisions: Explicitly not intended as medical devices for diabetes management

Regulatory Status Consumer CGM programs use FDA-cleared sensors but market them for wellness rather than medical purposes. The sensors themselves are approved medical devices; the wellness application is the differentiating factor.[10]

Evidence Limitations

• Behavioral intervention effectiveness requires further study
• Limited peer-reviewed research on metabolic health benefits in non-diabetic populations
• Glucose variability in healthy individuals not well-characterized
• Optimal glucose targets for wellness not established by medical consensus

Newly Diagnosed with Type 1 or Type 2 Diabetes

If you’ve been recently diagnosed, the most important first question is whether your treatment plan includes insulin.

With insulin: Your provider will almost certainly recommend a prescription CGM. The Dexcom G7 and FreeStyle Libre 3 are the most commonly prescribed options in 2026, both with strong insurance coverage pathways and iCGM compatibility for future AID system integration. Start by confirming your insurance covers CGM under pharmacy or DME benefits — most plans covering people with Type 1 diabetes include CGM coverage.

Without insulin (Type 2, oral medications): You have the most options. A prescription flash monitor, an OTC CGM (Stelo or Lingo), or even a traditional meter may all be appropriate starting points. An OTC CGM is worth considering if you want immediate real-time trend data without the prior authorization process — you can start within 24 hours of purchase.

CGM systems with alerts may reduce severe hypoglycemia episodes and improve time-in-range. randomized controlled trial in adults with Type 1 diabetes

Evidence for CGM benefit in type 2 diabetes is strongest for those on intensive insulin therapy.[3 – 2021 randomized trial in Type 2 diabetes patients on basal insulin]

Questions to ask your provider at your next visit:

• Does my insurance cover a prescription CGM?
• Do you have starter sensors or a trial program available?
• Should I start with a traditional meter while my insurance coverage is established?

Parents and Caregivers of Children with T1D

Managing a child’s diabetes — particularly overnight and during school hours — is one of the clearest clinical use cases for prescription CGM with remote monitoring capability.

The Dexcom G7 is FDA-cleared for use in children aged 2 years and older and supports the Dexcom Share feature, which transmits readings to a caregiver’s smartphone in real time. The FreeStyle Libre 3 supports the LibreLink sharing feature for caregivers. Both systems allow parents to receive automated low-glucose alerts even when the child is in a separate room, at school, or overnight.

Key features to confirm when selecting a device for a child:

• Age-appropriate FDA clearance (confirm with prescribing provider)
• Remote sharing capability and alert customization
• Adhesive durability for active children (overlay patches are widely available)
• School nurse integration — both Dexcom and Abbott provide school management resources

Athletes and Active Users

Exercise significantly affects glucose — and for insulin users, the stakes of glucose instability during training are high. CGMs provide real-time trend data that enables pre- and post-exercise fueling adjustments that no other monitoring method can match.

For insulin-using athletes: A prescription CGM with trend arrows is the standard recommendation. Trend arrows showing “glucose falling rapidly” during endurance exercise provide a preventive signal before hypoglycemia occurs — enabling a carbohydrate intake or insulin reduction response.

For athletes without diabetes: OTC CGMs (Stelo or Lingo) have gained significant traction among performance-focused individuals using real-time glucose data to optimize fueling, recovery, and sleep quality. The evidence base for CGM use in non-diabetic athletes is still developing; benefits are reported anecdotally and in small studies, but the physiological data can be useful for personalized sports nutrition work.

Note on exercise accuracy: CGM readings during intense exercise can lag behind or temporarily diverge from true blood glucose, particularly during high-intensity intervals when peripheral blood flow is reduced. This is a physiological limitation of interstitial measurement — not a sensor failure. Fingerstick confirmation is recommended for insulin dosing decisions during and immediately after exercise.

Long-Term Users Considering an Upgrade (Libre 2 → Libre 3 / G6 → G7)

If you’re currently using a FreeStyle Libre 2 or Dexcom G6 and evaluating an upgrade, the primary questions are accuracy improvement, sensor wear duration, and compatibility with your current app or AID system.

FreeStyle Libre 2 → FreeStyle Libre 3:
The Libre 3 is smaller (the world’s smallest CGM sensor as of 2024), moves from 14-day to 14-day wear with a one-piece applicator, and adds real-time data streaming to the LibreLink app (vs Libre 2’s scan-on-demand model). MARD improves from approximately 9.4% (Libre 2) to approximately 7.9% (Libre 3, Castorino et al., 2022). The Libre 3 also supports iCGM classification for AID system integration.

Dexcom G6 → Dexcom G7:
The G7 features a fully disposable one-piece sensor and transmitter (vs G6’s two-piece system), reduces the warm-up period from 2 hours to 30 minutes, and extends the Grace Period feature that allows continued sensor use beyond the 10-day wear window. MARD improves from approximately 9.0% (G6) to 8.2% (G7, Wadwa et al., 2022).

Prescription required for upgrades: Upgrading to a new device generation requires an updated prescription in most cases. Contact your provider or pharmacy to confirm.

People Without Diabetes: Is an OTC CGM Right for You?

OTC CGMs are increasingly used by people without diabetes for metabolic health monitoring, weight management, athletic performance, and general wellness. This is a legitimate and growing use case — and it is the primary driver of the OTC CGM market as of 2026.

What OTC CGM data can tell a non-diabetic user:

• How specific foods affect your postprandial glucose response
• Whether high-glycemic meals contribute to energy crashes
• How sleep quality and duration affect fasting glucose
• How different forms of exercise affect glucose before, during, and after training

What the evidence currently supports: The research on CGM use in non-diabetic populations is early-stage. Small studies have shown that individuals with normal glucose tolerance can use CGM data to guide dietary choices, but large-scale outcomes data does not yet exist for this population (Hall et al., 2018, Cell Metabolism, for continuous glucose monitoring in non-diabetic populations).

Is an OTC CGM worth it if you don’t have diabetes? The honest answer depends on your goals. If you’re looking for a short-term data experiment (2–4 weeks) to understand your personal glucose patterns, an OTC CGM is a reasonable investment at approximately $50–$99 for a trial period. If you’re seeking ongoing health monitoring, the cost-benefit analysis should include whether the data will lead to actionable behavioral change.

Recommendation: Discuss CGM use with your primary care provider before starting, particularly if you have prediabetes, a family history of diabetes, or any metabolic health concerns.

CGM for Elderly Adults and Remote Family Monitoring

For elderly adults with diabetes, CGM provides two distinct benefits beyond glucose management: reduced fingerstick burden (critical for users with limited manual dexterity or vision impairment) and remote monitoring capability for family caregivers.

The Dexcom G7 and FreeStyle Libre 3 both support caregiver sharing apps that allow an adult child or family member to monitor an elderly parent’s glucose in real time, receiving low and high glucose alerts on their own device.

Medicare coverage: As of 2023, Medicare covers therapeutic CGMs for beneficiaries with diabetes who are treated with insulin or have a history of problematic hypoglycemia — including those on non-insulin injectable therapies. Medicare coverage expanded to include CGMs for non-insulin-using people with diabetes in 2023. Confirm current Medicare CGM eligibility with your provider or a Medicare-certified DME supplier.

CGM Accuracy Metrics

Modern CGM systems report Mean Absolute Relative Difference (MARD):

• MARD <10%: Considered clinically accurate
• Dexcom G7: ~8% MARD[7] clinical accuracy study of the Dexcom G7 system
• FreeStyle Libre 3: ~7.9% MARD[8] clinical evaluation of 14-day sensor accuracy

Practical considerations for elderly users:

• One-piece applicators (Dexcom G7, FreeStyle Libre 3) are easier to apply than two-piece systems
• Dedicated receivers are available for users who do not use smartphones
• Adhesive overlays are recommended for users with fragile skin

Prescription CGM Costs With and Without Insurance

Prescription CGM costs depend heavily on insurance coverage, manufacturer, and whether you purchase through a pharmacy or durable medical equipment (DME) supplier.

Verify current pricing at manufacturer websites and your pharmacy benefit manager before purchasing. Prices as of June 2026 are estimates and subject to change.

Important cost variables:

• Pharmacy vs DME: Prescription CGMs can be dispensed through your pharmacy benefit or your DME (durable medical equipment) benefit — whichever results in lower out-of-pocket cost. Check both pathways with your insurer.
• Manufacturer savings programs: Dexcom and Abbott both offer patient assistance programs and savings cards for people who are underinsured or uninsured. Visit the manufacturer’s website directly for current eligibility.
• Receiver cost: Most CGMs can transmit directly to a smartphone, making a separate receiver optional. If you need a dedicated receiver (required for some older models), budget an additional one-time cost of $80–$120.

OTC CGM Pricing: Stelo, Lingo, and Libre Rio

OTC CGMs are purchased directly — no insurance claim, no DME supplier, no prior authorization. Pricing follows a subscription or per-sensor model.

Prices are subject to change. Confirm current pricing at myabbottlingo.com, dexcom.com/stelo, or your pharmacy. FreeStyle Libre Rio pricing varies by retailer.

OTC CGMs are not covered by most insurance plans. Because they are classified as general wellness or non-prescription devices, OTC CGMs are typically not reimbursable under standard pharmacy or DME benefits. FSA and HSA funds may be eligible — check with your account administrator.

OTC vs prescription cost comparison: If you have insurance that covers a prescription CGM, the prescription route will almost always be less expensive than an OTC device. OTC CGMs are most cost-effective for people who do not have insurance CGM coverage, who do not have a diabetes diagnosis, or who want short-term monitoring without a provider visit.

How to Get Insurance to Cover a CGM for Type 2 Diabetes

To appeal a CGM insurance denial:

1. Request the formal denial letter with reason codes from your insurer.
2. Ask your provider to submit a Letter of Medical Necessity citing ADA Standards of Care 2024 recommendations for CGM use.
3. Reference your plan’s specific CGM coverage criteria in the appeal.
4. Submit within the timeframe stated in the denial letter — typically 30–180 days. First-level appeals for insulin-using patients with proper documentation have high success rates.

Insurance coverage for CGMs in Type 2 diabetes has improved substantially since 2023, but the prior authorization process remains the most common barrier for people who are not on insulin. Here is a step-by-step process for navigating a CGM coverage request or appeal.

Step 1: Confirm your plan’s CGM coverage criteria.
Call the member services number on your insurance card and ask specifically: “Does my plan cover CGMs for Type 2 diabetes? What are the coverage criteria?” Most commercial plans require either insulin use, a documented history of hypoglycemia, or a treating physician’s recommendation. Get the criteria in writing if possible.

Step 2: Ask your provider to submit a prior authorization (PA) request.
Your prescribing provider — endocrinologist or primary care physician — initiates the PA. The PA should include your diagnosis, current treatment regimen, HbA1c levels, and a clinical rationale citing the ADA Standards of Care, which recommend CGM consideration for any person with diabetes on multiple daily injections or who has hypoglycemia unawareness (ADA Standards of Care, 2024).

Step 3: If denied, request the formal denial letter with reason codes.
A denial is not final. Request the denial in writing with the specific reason codes. Common denial reasons include “not medically necessary” or “not on insulin” — both are appealable with appropriate documentation.

Step 4: Submit a first-level appeal with a Letter of Medical Necessity.
Your provider writes a Letter of Medical Necessity citing:

• Your current glucose management challenges
• Clinical evidence supporting CGM (ADA Standards of Care; relevant peer-reviewed studies)
• The expected clinical benefit for your specific situation

Step 5: Reference your plan’s internal appeals process timeline.
Most plans are required to respond to a first-level appeal within 30 days (non-urgent) or 72 hours (urgent/expedited). Submit within the timeframe stated in your denial letter — typically 30–180 days from the denial date.

Success rates: First-level CGM appeals with proper documentation — particularly for Type 1 diabetes and insulin-using Type 2 patients — have high success rates. The ADA’s Standards of Care documentation is the most commonly cited reference in successful appeals.

Medicare CGM Coverage: Who Qualifies in 2026

Medicare CGM coverage expanded significantly in 2023 and 2024. Here is the current eligibility landscape:

Who qualifies for Medicare CGM coverage:

• People with diabetes who are treated with insulin (any number of daily injections)
• People with diabetes with a history of problematic hypoglycemia (severe lows requiring assistance)
• As of 2023: people with diabetes who are not on insulin but have a documented need for continuous glucose data, as determined by their treating provider

How Medicare covers CGMs:
CGMs are covered under Medicare Part B as Durable Medical Equipment (DME). You pay 20% of the Medicare-approved amount after your Part B deductible is met. Supplemental insurance (Medigap) may cover some or all of the 20% coinsurance.

Prescription CGMs covered by Medicare include: Dexcom G7, FreeStyle Libre 3, FreeStyle Libre 2 Plus, and Medtronic Guardian 4 (subject to DME supplier availability and local coverage determinations).

OTC CGMs are not covered by Medicare. Stelo, Lingo, and Libre Rio are not reimbursable under Medicare Part B or Part D as of June 2026.

To access Medicare CGM coverage:

1. Obtain a prescription from your treating provider (must be enrolled in Medicare)
2. Purchase through a Medicare-certified DME supplier (not all pharmacies are DME-certified)
3. Ensure your provider documents your CGM need in your medical record — Medicare may audit claims

Confirm current eligibility with your provider or a Medicare-certified DME supplier, as coverage policies update periodically. Medicare Coverage (as of 2026):[9] Centers for Medicare & Medicaid Services national coverage policy

What MARD Means for Your Glucose Readings

TL;DR:

Mean Absolute Relative Difference (MARD) is the standard clinical accuracy metric for continuous glucose monitors, expressing the average percentage difference between a CGM reading and a reference blood glucose measurement. A lower MARD indicates higher accuracy. The FreeStyle Libre 3 reports approximately 7.9% MARD (Castorino et al., 2022, Diabetes Technology & Therapeutics) and the Dexcom G7 reports 8.2% MARD (Wadwa et al., 2022, Diabetes Technology & Therapeutics) — both representing clinically meaningful accuracy for diabetes management.

Mean Absolute Relative Difference (MARD) is the standard clinical accuracy metric for continuous glucose monitors, expressing the average percentage difference between a CGM reading and a simultaneous reference blood glucose measurement. A lower MARD indicates a more accurate device: a MARD of 8% means the CGM reading differs from a laboratory-grade measurement by approximately 8% on average.

Among currently marketed prescription CGMs, the FreeStyle Libre 3 reports approximately 7.9% MARD (Castorino et al., 2022, Diabetes Technology & Therapeutics) and the Dexcom G7 reports 8.2% MARD (Wadwa et al., 2022, Diabetes Technology & Therapeutics). Both figures represent a clinically meaningful improvement over earlier CGM generations, which commonly reported MARD values in the 9–12% range.

What MARD does not measure: MARD is an average. It does not capture performance in rapidly changing glucose conditions (e.g., post-meal spikes, exercise-induced drops), where CGM readings may lag 5–15 minutes behind true blood glucose due to the physiology of interstitial fluid. MARD figures are also validated under controlled study conditions; real-world accuracy can vary based on sensor placement, hydration, and skin temperature.

Device Accuracy Compared: CGM vs Flash vs Traditional Meter

Evidence on Accuracy Studies comparing CGM systems to reference glucose measurements show MARD values ranging from 8.7% to 12.4% across current systems, with newer generations generally showing improved accuracy

Factors That Affect CGM Accuracy

CGM accuracy may vary with:

• Glucose range (less accurate at very low or very high values)
• Rate of glucose change (rapid changes increase lag effect)
• Sensor placement and insertion quality
• Individual physiological factors
• Days of sensor wear (some drift over time)

Time-in-Range (TIR) vs HbA1c — Which Matters More?

TL;DR:

Time-in-Range (TIR) is the percentage of a 24-hour period during which glucose stays between 70 and 180 mg/dL. The American Diabetes Association recommends a TIR above 70% for most non-pregnant adults with diabetes and above 63% during pregnancy (ADA Standards of Care, 2024). Unlike HbA1c — which reflects a 90-day glucose average — TIR captures daily glucose variability, making it the more actionable metric for people using CGMs to adjust behavior in real time.

What is Time-in-Range (TIR)? Time-in-Range is the percentage of a 24-hour period during which your glucose level stays between 70 and 180 mg/dL. The American Diabetes Association recommends a TIR target above 70% for most non-pregnant adults with Type 1 or Type 2 diabetes, and above 63% during pregnancy, with a tighter glucose band of 63–140 mg/dL (ADA Standards of Care, 2024).

TIR vs HbA1c — what’s the difference? HbA1c measures your average blood glucose over the preceding 90 days and remains the standard quarterly clinical benchmark. TIR, measured only by a CGM or flash monitor, captures hour-to-hour glucose fluctuation that HbA1c cannot detect. A person could maintain an HbA1c of 7.0% while experiencing frequent dangerous lows offset by post-meal highs — a dangerous pattern TIR would surface and HbA1c would mask entirely.

For CGM users, TIR is generally the more actionable daily metric: you can see it change within hours of a dietary or behavioral adjustment. HbA1c, reviewed quarterly, remains the gold standard for long-term clinical assessment and insurance coverage determinations.

Definition and Clinical Targets

Time-in-Range (TIR) represents percentage of time glucose stays within target:

Goals may vary based on individual factors including age, pregnancy, and hypoglycemia awareness.[11] American Diabetes Association’s 2024 standards for glycemic targets

Both metrics complement each other in diabetes management.

Coefficient of Variation (CV): Measuring Glucose Variability

What is Coefficient of Variation (CV) in glucose monitoring? Coefficient of Variation (CV) measures how much your glucose levels fluctuate relative to your average glucose. It is calculated as the standard deviation of glucose readings divided by the mean glucose, expressed as a percentage. A CV below 36% is the target recommended by the Ambulatory Glucose Profile (AGP) consensus guidelines, indicating stable, predictable glucose patterns (Danne et al., 2017, Diabetes Care).

High CV — typically above 36% — suggests frequent glucose swings that increase the risk of both hypoglycemia and hyperglycemia events, even when average glucose or HbA1c appears controlled. CGM enables continuous CV tracking; traditional fingerstick meters do not generate enough data points to calculate a meaningful CV.

Why CV matters: Two people with identical HbA1c values can have very different CVs. The person with the higher CV is experiencing more glucose instability — which carries independent risks for cardiovascular and microvascular complications, separate from average glucose levels.

Coefficient of Variation

Glucose variability measured as:

CV = (Standard Deviation ÷ Mean Glucose) × 100

• CV <36%: Target for stable glucose control
• CV >36%: Indicates high glucose variability

High variability may increase diabetes complication risk independent of average glucose.

Managing Variability

• Factors contributing to glucose variability:
• Sleep quality and stress
• Inconsistent carbohydrate intake
• Irregular meal timing
• Variable physical activity
• Medication adherence

Ambulatory Glucose Profile (AGP): The Clinical Reporting Standard

What is an Ambulatory Glucose Profile (AGP)? The Ambulatory Glucose Profile (AGP) is a standardized one-page glucose report generated by CGM data, displaying median glucose, percentile bands (10th, 25th, 75th, 90th), and TIR statistics across a 14–90 day period. The AGP is the internationally endorsed reporting format for CGM data review in clinical settings (Danne et al., 2017, Diabetes Care).

AGP reports are generated automatically by most prescription CGM systems — including the Dexcom Clarity app and Abbott LibreView — and can be shared directly with an endocrinologist before a clinic visit, enabling data-driven medication and lifestyle adjustments without requiring in-office glucose log review.

Who benefits from AGP review: Any person using a CGM or flash monitor whose provider reviews CGM data at clinic visits. AGP standardization means a Dexcom user and a Libre user can present their glucose patterns on the same report template, enabling provider-patient discussion without proprietary app navigation.

Standardized Report Format

The Ambulatory Glucose Profile (AGP) presents CGM data in clinical format:

AGP Components:

• Median glucose curve (typical daily pattern)
• Interquartile range (25th-75th percentile)
• 10th-90th percentile range
• Target range visualization
• Daily glucose profiles overlaid

Clinical Interpretation

AGP reports help healthcare providers:

• Identify consistent patterns vs. one-time events
• Assess overnight glucose control
• Evaluate post-meal glucose responses
• Guide medication timing adjustments

Patients can generate AGP reports for medical appointments through device software.

When to Consult a Healthcare Provider

The information on this page is designed to help you arrive at a provider conversation better prepared — not to replace that conversation.

Consult a healthcare provider before starting a CGM if:

• You have been diagnosed with any form of diabetes (a CGM prescription requires provider involvement for insurance coverage and clinical appropriateness)
• You are pregnant or planning to become pregnant
• You have any skin condition, implanted electronic device (pacemaker, cochlear implant), or medication regimen that may interact with wearable sensor devices
• You are considering an OTC CGM but have a first-degree family member with diabetes — a provider can assess whether a prediabetes evaluation is appropriate first

Consult a healthcare provider immediately if:

• Your CGM is showing sustained readings below 70 mg/dL that do not resolve with carbohydrate intake
• You experience symptoms of hypoglycemia (shakiness, confusion, sweating) that your CGM does not capture
• You notice consistent CGM readings that conflict significantly with your physical symptoms

All content on this page has been medically reviewed by Dr. Rishav Das, M.B.B.S. (ORCID: 0009-0007-2692-4542). This page does not constitute medical advice. Glucose monitoring decisions should be made in partnership with a qualified healthcare provider.

Ready to Choose Your Device? Here’s Your Next Step.

The comparison tables and decision guides above cover every major glucose monitor category. Glucose monitoring is ultimately a clinical decision that should involve your endocrinologist or primary care provider — but arriving at your appointment with a 1–2 device shortlist typically leads to faster, better-matched prescribing decisions.

Use the action steps below based on your situation:

→ Newly diagnosed with diabetes:
Ask your provider whether you qualify for a prescription CGM under your insurance plan, and whether a starter sensor trial is available. Bring the accuracy table from this page to your first appointment.

→ Managing T2D without insulin, or exploring metabolic health:
Ask your provider whether Dexcom Stelo or Abbott Lingo would generate useful data for your management plan. Both are available without a prescription at major pharmacy chains — no provider visit required to start.

→ Dealing with an insurance denial:
Review our CGM Insurance Approval Guide before resubmitting. A properly documented first-level appeal with a Letter of Medical Necessity resolves the majority of initial denials.

→ Not sure which type fits your situation:
Return to the Quick Match table at the top of this page, or use the Device Selection by Clinical Use Case section to identify the right category before booking a provider appointment.

All content on this page has been medically reviewed by Dr. Rishav Das, M.B.B.S. Clinical decisions should be made in partnership with a qualified healthcare provider who knows your full medical history.

Connect with the Glucose Monitoring Community

You’re not alone in navigating diabetes technology. These resources provide support, real-world experiences, and ongoing education:

Online Communities and Support Groups

• Diabetes Daily Forums (diabetesdaily.com): Active community discussing all device types with user reviews
• Beyond Type 1 (beyondtype1.org): Type 1-focused organization with CGM troubleshooting guides
• TuDiabetes (tudiabetes.org): Peer support community with device comparison discussions
• Facebook Groups: “CGM Users,” “FreeStyle Libre Users,” “Dexcom G7 Community” (search Facebook for closed support groups)

Video Resources

• Search YouTube for device-specific channels: “Dexcom sensor insertion,” “FreeStyle Libre application,” “CGM accuracy testing”
• Diabetes educators often post troubleshooting tips and comparison videos
• User testimonials provide realistic expectations beyond manufacturer marketing

Manufacturer Resources

• 24/7 Technical Support Hotlines: All major manufacturers provide phone support for device issues
• Educational Webinars: Free training sessions on maximizing device benefits
• Customer Portals: Access to replacement supplies, insurance assistance, and troubleshooting guides

Healthcare Provider Collaboration

• Certified Diabetes Educators (CDEs): Specialists who provide device training and data interpretation
• Endocrinology Offices: Many have manufacturer representatives visit regularly with sample devices and application demonstrations

Share This Resource

Found this guide helpful? Share with others navigating glucose monitoring decisions:

• – Send to family members helping with diabetes management
• – Share in diabetes support groups or forums
• – Print for discussion at your next doctor appointment
• – Forward to friends newly diagnosed with diabetes

References

[1] Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. (2008). Continuous glucose monitoring and intensive treatment of type 1 diabetes. New England Journal of Medicine, 359(14), 1464-1476.

[2] Beck, R. W., et al. (2017). Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA, 317(4), 371-378.

[3] Martens, T., et al. (2021). Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: A randomized clinical trial. JAMA, 325(22), 2262-2272.

[4] Bolinder, J., et al. (2016). Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: A multicentre, non-masked, randomised controlled trial. Lancet, 388(10057), 2254-2263.

[5] U.S. Food and Drug Administration. (2020). Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use: Guidance for Industry and Food and Drug Administration Staff.

[6] Klonoff, D. C., et al. (2022). The pursuit of noninvasive glucose monitoring: A review of currently available devices and recent advances. Diabetes Technology & Therapeutics, 24(11), 739-752.

[7] Wadwa, R. P., et al. (2022). Accuracy of a factory-calibrated, real-time continuous glucose monitoring system during 10 days of use in youth and adults with diabetes. Diabetes Technology & Therapeutics, 24(2), 95-105.

[8] Castorino, K., et al. (2022). Performance evaluation of the FreeStyle Libre 3 system: Real-world evidence from a prospective observational study. Diabetes Technology & Therapeutics, 24(8), 540-548.

[9] Centers for Medicare & Medicaid Services. (2023). National Coverage Determination for Continuous Glucose Monitors (CGMs) (CAG-00459N).

[10] U.S. Food and Drug Administration. (2022). General Wellness: Policy for Low Risk Devices – Guidance for Industry and Food and Drug Administration Staff.

[11] American Diabetes Association. (2024). Glycemic targets: Standards of care in diabetes—2024. Diabetes Care, 47(Supplement_1), S111-S125.

[12] Aleppo, G., et al. (2022). MOBILE study: Performance and patient satisfaction with the MiniMed 780G system. Diabetes Technology & Therapeutics, 24(9), 607-615.

[13] Reddy, M., et al. (2023). Effect of continuous glucose monitoring on quality of life and glucose control in type 2 diabetes: A meta-analysis. Diabetes Care, 46(5), 1033-1041.

[14] American Diabetes Association. (2024). Classification and diagnosis of diabetes: Standards of care in diabetes—2024. Diabetes Care, 47(Supplement_1), S20-S42.